Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy
| Autor: | G. Curto, Florena M, Antonio Testa, Nicola Gebbia, Calogero Cipolla, Nicola Borsellino, Ignazio Carreca, Roberto Valenza, G Cannata, Mario Adelfio Latteri, Vittorio Gebbia |
|---|---|
| Přispěvatelé: | Gebbia, V., Carreca, I., Testa, A., Valenza, R., Curto, G., Cannata, G., Borsellino, N., Latteri, M., Cipolla, C., Florena, M., Gebbia, N. |
| Jazyk: | angličtina |
| Rok vydání: | 1993 |
| Předmět: |
Diarrhea
Male Loperamide medicine.medical_specialty Abdominal pain Cancer Research medicine.medical_treatment Injections Subcutaneous Octreotide Administration Oral Gastroenterology law.invention Randomized controlled trial law Chemotherapy-related diarrhea Internal medicine Neoplasms Antineoplastic Combined Chemotherapy Protocols Medicine Humans Pharmacology (medical) Pharmacology Chemotherapy business.industry Middle Aged Clinical trial Endocrinology Oncology Defecation Female medicine.symptom business medicine.drug |
| Zdroj: | Scopus-Elsevier |
| Popis: | Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose bowel movements within 4 days of therapy, while in the loperamide group this goal was obtained in only 30% of cases (p < 0.001). If after 4 days no benefit was seen, patients were considered to have failed antidiarrheal therapy. Failure was recorded in only one case (5%) treated with s.c. octreotide and in five patients (25%) who received loperamide. The mean duration of antidiarrheal therapy necessary to achieve remission was 3.4 days in the octreotide group and 6.1 days in the loperamide group (p < 0.001). Treatment with octreotide was very well tolerated with mild abdominal pain in 15% of cases and pain in the injection site in 15% of patients. Subcutaneous octreotide is highly effective in the management of chemotherapy-related diarrhea in cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|